ArticleTranslational cancer research2021
Is metabolic syndrome associated with high tumor grade and stage of bladder cancer: a systematic review and meta-analysis.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Which Surrogate Marker of Insulin Resistance Among Those Proposed in the Literature Better Predicts the Presence of Non-Metastatic Bladder Cancer?Journal of clinical medicine · 2025Article
- Metabolic syndrome and the risk of severe cancer events: a longitudinal study in Japanese workers.BMC cancer · 2023Article
- Can Diet Prevent Urological Cancers? An Update on Carotenoids as Chemopreventive Agents.Nutrients · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of our study was to elaborate the association between metabolic syndrome (MS) and the tumor stage and grade of bladder cancer (BC).
methodsA systematic review and pooled analysis on PubMed, the Cochrane Library, Embase, Web of Science, CNKI, WANFANG and VIP from databases inception to July 24, 2020 was conducted by two independent authors. Relative risk (RR) was used as pooled effect estimates. The data analysis was accomplished by STATA 14.2.
resultsThree English and four Chinese articles were included in the final analysis. A pooled analysis of six studies showed that patients in MS group were at a 1.94-fold risk of high-stage BC when compared to their counterparts (RR: 1.94; 95% CI: 1.59-2.37), and the difference was statistically significant. For the components of MS, except for hypertension, patients with obesity (RR: 1.61; 95% CI: 1.33-1.95), hyperglycemia (RR: 2.20; 95% CI: 1.49-3.26) and low high-density lipoprotein cholesterol (HDL) (RR: 1.98; 95% CI: 1.51-2.58) had significantly higher risks of high-stage BC than the control groups. A pooled analysis of six studies indicated that MS can contribute substantially to the vulnerability of high-grade BC with significant difference (RR: 1.50; 95% CI: 1.37-1.65). Furthermore, patients with obesity (RR: 1.41; 95% CI: 1.18-1.69), hyperglycemia (RR: 1.42; 95% CI: 1.30-1.56), hypertension (RR: 1.13; 95% CI: 1.03-1.24), low HDL (RR: 1.29; 95% CI: 1.14-1.46) and high triglyceride (TG) (RR: 1.28; 95% CI: 1.11-1.46) were at a higher risk of high-grade BC than their counterparts.
conclusionsThis meta-analysis revealed that MS and its components might be associated with high BC stage and grade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.